Today’s the day that every company that received JobKeeper has to disclose the proceeds.

While many ASX companies have already done so, all who haven’t will have their proceeds listed on ASIC’s website.

The massive wage subsidy scheme was instituted in March 2020 as an attempt to stabilise the economy, after thousands of workers were stood down or laid off due to the pandemic.

While inevitably some companies needed the scheme, other recipients still took the funds while also getting a welcome boost to their business, as a result of the unique operating conditions created by the pandemic.

Of the latter group, some have returned the proceeds but others have only returned a portion of the funds. A small group of JobKeeper winners is yet to return any money at all.

On the ASX the largest recipient to have disclosed so far is Qantas (ASX:QAN) which received over $700 million.

To markets…

The ASX has notched up its biggest gain in a fortnight heading into midday trade, with the ASX 200 trading 0.59% higher today.

It followed a strong session on Wall Street, as investors shrugged off lingering fears over the omicron COVID-19 variant.

On the home front, Queensland announced that it will re-open its borders to vaccinated travellers from the rest of the country.

This afternoon, the RBA will meet for the last time this year and while a rate change is not expected for several months, it will be the first meeting since the omicron variant was first discovered.

“No policy changes are expected even as the GDP print showedeconomic activity had held upbetter than expected over the lockdown period,” CBA economist Stephen Wu said.


Here are the best performing ASX small cap stocks for December 7 [intraday]:

Swipe or scroll to reveal full table. Click headings to sort:

Code Name Price % Change Volume
NEU Neuren Pharmaceut. 3.34 96 5564506
ANL Amani Gold Ltd 0.0015 50 5035013
AHI Adv Human Imag Ltd 1.115 27 1305073
RVS Revasum 0.56 27 159545
CGB Cann Global Limited 0.0025 25 508425
CXU Cauldron Energy Ltd 0.028 22 362275
ADR Adherium Ltd 0.012 20 46998
RDS Redstone Resources 0.013 18 633254
BKT Black Rock Mining 0.215 16 2551661
AYM Australia United Min 0.008 14 123565
BRV Big River Gold Ltd 0.245 14 10079
TYM Tymlez Group 0.033 14 9371133
LMG Latrobe Magnesium 0.087 13 9919132
SOR Strategic Elements 0.225 13 1419348
AO1 Assetowl Limited 0.0045 13 268600
EVE EVE Health Group Ltd 0.0045 13 725000
RAN Range International 0.018 13 1286708
SKT Sky Network 1.9 12 156326
PH2 Pure Hydrogen Corp 0.465 12 2844177
MNB Minbos Resources Ltd 0.14 12 778514
TNT Tesserent Limited 0.1675 12 3856585
ABE Ausbondexchange 0.59 11 779148
WordPress Tables Plugin

Neuren Pharmaceuticals (ASX:NEU) nearly doubled off the back of its Phase III clinical trial results.

The study evaluated trofinetide in 187 girls and young women aged 5-20 years with Rett syndrome, a serious neurological disorder that emerges in early childhood. Neuren’s US partner Acadia said that trofinetide has met co-primary efficacy endpoints, demonstrating statistically significant improvement over placebo.

Acadia plans a Pre-New Drug Application meeting with the FDA in Q1 2022, and New Drug Application (NDA) around mid-year 2022.

In resources, one winner was Tanzanian focused graphite developer Black Rock Mining (ASX:BKT) which told shareholders it had been invited to a ceremony with the Tanzanian government to finalise an agreement with the country’s government.

Many ASX explorers focused on Tanzania, pivoted after new mining regulations in 2017 but Black Rock has stuck with it and the new administration appears more friendly to the sector (at least for now).

And Strategic Elements (ASX:SOR) revealed it had won a a patent in Japan for its Nanocube Memory Ink technology.